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Abstract 11 
Introduction: Although multiple efforts have been initiated to shed light into the molecular 12 
mechanisms underlying cardiovascular disease, it still remains one of the major causes of 13 
death worldwide. Proteomics approaches are unequivocally powerful tools that may provide 14 
deeper understanding into the molecular mechanisms associated with cardiovascular 15 
disease and improve its management.  16 
Areas covered: Cardiovascular proteomics is an emerging field and significant progress has 17 
been made during the past few years with the aim of defining novel candidate biomarkers 18 
and obtaining insight into molecular pathophysiology. To summarize the recent progress in 19 
the field, a literature search was conducted in PubMed and Web of Science. As a result, 704 20 
studies from PubMed and 320 studies from Web of Science were retrieved. Findings from 21 
original research articles using proteomics technologies for the discovery of biomarkers for 22 
cardiovascular disease in human are summarized in this review.  23 
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Expert commentary: proteins associated with cardiovascular disease represent pathways in 24 
inflammation, wound healing and coagulation, proteolysis and extracellular matrix 25 
organization, handling of cholesterol and LDL. Future research in the field should target to 26 
increase proteome coverage as well as integrate proteomics  with other omics data to 27 
facilitate both drug development as well as clinical implementation of findings. 28 
Keywords: cardiovascular disease, vascular disease, proteome, biomarker, clinical 29 
proteomics 30 
 31 
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1. Introduction 33 
Cardiovascular disease (CVD) is the leading cause of death worldwide with a high mortality 34 
rate and an increasing incidence annually. Since it represents a major contributor to the 35 
global disease burden, gaining insights into the mechanisms of CVDs is emergent. CVD is a 36 
complex disorder describing pathophysiological conditions of the heart and blood vessels 37 
and includes a wide range of diseases such as coronary artery disease (CAD), heart failure 38 
(HF), myocardial infarction (MI), abdominal aortic stenosis, ischemic stroke, cardiomyopathy 39 
etc [1]. Several factors such as lifestyle, diet, (epi)genetics, dyslipidemia, hypertension, and 40 
inflammation are associated with the onset and development of CVD. Addressing the 41 
standard risk factors for CVD including hypertension, diabetes mellitus, smoking, and 42 
hypercholesterolemia is a major aim in the prevention of CVD. Nevertheless, the current 43 
treatment schemes, by addressing these individual risk factors, have not fully provided 44 
either a significant progress in curative treatment or a full understanding of the disease. 45 
Over the past years, efforts to elucidate the key molecular mechanisms underlying CVD were 46 
undertaken. Its complex etiology and the plethora of the different factors that are 47 
responsible for the observed pathology, require the development of more holistic treatment 48 
approaches targeting the underlying mechanisms [2]. The development and application of 49 
systems biology approaches for CVD investigation is an active and challenging research field 50 
[2-4]. 51 
Integrated omics approaches, including genomics/epigenomics, transcriptomics, proteomics, 52 
metabolomics have gained momentum the past few years. They provide information at 53 
multiple biological levels from the DNA and RNA to the protein and metabolite patterns, 54 
offering a different perspective on the molecular and cellular networks of whole organ 55 
system. Although, genomic and transcriptomic strategies have been recently applied in CVD 56 
4 
 
research, the weakness of these strategies is that they cannot correlate easily the observed 57 
changes to the expression of proteins and additionally, they cannot characterize the post-58 
translational modifications (PTM) which play critical role in the regulation of many biological 59 
processes. These shortcomings can be addressed by the application of proteomic 60 
approaches. In fact, proteomic changes are likely the cause of most non-communicable 61 
diseases, including CVD, and interfering drugs generally act via targeting specific proteins. As 62 
graphically depicted in Figure 1, based on these facts it appears evident that the proteome 63 
will inform with superior accuracy on (any) disease, and on the best suited therapeutic 64 
intervention, leading towards personalized medicine. 65 
Two main strategies appear of relevance in the exploitation of proteomic changes in the 66 
context of CVD: 1) obtain information about molecular pathophysiology and enable 67 
identifying relevant targets for intervention, and 2) identification of biomarkers that support 68 
patient management and guide therapy. As depicted in Figure 2, these two strategies do 69 
have different requirements. While implementation of a biomarker requires very high 70 
confidence in a biomarker and the test to be used (needs to be verified in large cohorts, 71 
likely exceeding 1000 subjects, and needs to demonstrate a significant improvement over 72 
the current state of the art), knowledge on the specific role of the biomarker in the 73 
molecular pathology is not a prerequisite for its employment (e.g even if we do not know 74 
why a patient has fever or elevated blood pressure, we nevertheless typically act upon 75 
detection of a significant change from the reference range in these biomarkers). In contrast, 76 
identifying drug targets requires in depth knowledge on molecular pathology. A major 77 
prerequisite to unravel the biological processes and pathways (and to consequently enable 78 
identifying the best suited drug targets) is a comprehensive coverage of the proteomic 79 
changes in the respective disease. To enable such in depth coverage, reduced stringency in 80 
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statistical evaluation needs to be accepted; it is impossible to verify ideally thousands of 81 
(sometimes) subtle changes observed in disease. 82 
To review the current status of proteomic biomarkers associated with CVD, we conducted a 83 
literature search in PubMed using the keywords [proteomic; biomarker; cardiovascular 84 
disease] or the search query [cardiovasc*and proteom* and marker or biomarker] in the 85 
Web of Science. Following this combined search, 704 studies from PubMed and 320 from 86 
Web of Science published between January 2010 and October 2016) were initially retrieved. 87 
Studies focusing on animal models and reviews were excluded. Only studies in human using 88 
proteomics technologies for the discovery of biomarkers in cardiovascular disease were 89 
included (all listed as supplementary table). Based on these articles, we discuss in this review 90 
the recent advances in the development of specific biomarkers for CVD through the 91 
application of state of the art proteomic technologies and the progress that was made 92 
towards their clinical implementation. The general workflow that is followed in these studies 93 
and the molecules that are currently being used as CVD biomarkers in the clinical routine is 94 
shown in Figure 3. A brief overview of main employed proteomics platforms and types of 95 
specimens analyzed in CVD research, followed by a more detailed presentation of biomarker 96 
findings, as retrieved from the aforementioned literature search, follow. 97 
 98 
2. Overview of the state of the art proteomics technologies in CVD 99 
Quantitative methods can be divided into global and targeted proteomic approaches. The 100 
global approaches compare two or more proteomes for the identification of the 101 
differentially expressed proteins under physiological and pathological conditions and can be 102 
applied to the unbiased discovery of biomarkers. Global approaches are further categorized 103 
into gel based and gel free [Liquid chromatography-tandem mass spectrometry (LC-MS/MS) 104 
6 
 
based]. Gel based approaches, such as two-dimensional electrophoresis (2DE) and two-105 
dimensional Differential-In-Gel-Electrophoresis (2D-DIGE), have contributed in CVD [5-8]. 106 
However, 2DE is of lower resolving power in comparison to LC-MS/MS, allowing, by now, to 107 
assess with good confidence > 1000 proteins in complex mixtures per experiment.  108 
As a result, LC-MS/MS has become a commonly employed method due to its sensitivity and 109 
high resolving power. There are two main strategies to perform quantitative proteome 110 
analysis, by either using label-free strategies where the peptides from 2 or more samples are 111 
injected into the mass spectrometer and analyzed in individual LC-MS experiments or by 112 
using the isotope labeling approaches. Labeling proteomic approaches include stable isotope 113 
labeling by amino acids in cell culture (SILAC), in which isotopically labeled amino acids are 114 
incorporated into cell culture media, as well as isobaric tags for relative and absolute 115 
quantification (iTRAQ) [9] or tandem mass tags (TMT), applicable to the study of any type of 116 
biological samples (beyond cell cultures) [10]. In a recent study, employing multiplexed 117 
iTRAQ, intensive depletion of abundant plasma proteins, optimized fractionation methods 118 
along with the use of the latest mass spectrometry (MS) instrumentation on plasma samples 119 
from patients undergoing a therapeutic, planned myocardial infarction (PMI) for treatment 120 
of hypertrophic cardiomyopathy [11], about 5000 proteins were identified in one analysis. 121 
In studies that focus on analyzing a large number of heterogeneous samples containing 122 
interfering compounds such as lipids, the use of capillary electrophoresis coupled to mass 123 
spectrometry (CE-MS) appears advantageous [12]. This technique has been applied for the 124 
proteomic analysis of urine and has enabled the identification of novel candidate biomarkers 125 
in CAD [13], stroke [14], HF [15] and deep vein thrombosis [16]. These studies are 126 
summarized in the following sections. 127 
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Targeted proteomic approaches characterize and quantify a limited number of known target 128 
proteins from a complex sample. Their application includes a follow-up on proteins 129 
identified from global/unbiased proteomics screening, conducting functional studies such as 130 
post-translational modification (PTM) analysis and validation of biomarker candidates. 131 
Selected reaction monitoring (SRM) or multiple reaction monitoring (MRM) is frequently 132 
employed in targeted proteomics and has been applied for biomarker [17-19] and PTM 133 
quantification [20,21]. In some instances SRM has been combined with the Protein standard 134 
absolute quantification (PSAQ) strategy, which uses full-length isotope-labeled protein 135 
standards to quantify target proteins. The PSAQ-SRM method was used for the 136 
quantification of four biomarkers (LDH-B, CKMB, myoglobin and troponin I) in MI patients’ 137 
sera with good accuracy and reproducibility [22]. 138 
In recent years, array-based techniques have also been applied in order to identify 139 
biomarkers in atherosclerosis [23,24], abdominal aortic aneurism (AAA) [25] and CAD [26]. 140 
Additionally, aptamer-based proteomics have been applied for the identification of low-141 
abundance biomarkers in CVD [27]. However, due to the small sample size and the lack of 142 
validation studies, the value of these approaches cannot be assessed yet.  143 
 144 
3. Samples for proteome analysis in CVD 145 
3.1 Tissue 146 
Tissue proteomics in CVD have generated insight into the proteome of atherosclerotic 147 
plaques [6,7] and thrombi [28]. Although a number of studies have focused on the 148 
proteomic analysis of the whole atheromatous tissue of carotid and coronary arteries, this 149 
approach suffers from the existence of different layers; the adventitial, the medial and the 150 
intima. The latter represents the layer where a wide variety of changes occur upon 151 
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atherosclerosis development and progression. To overcome this barrier, arterial tissue 152 
subproteomes isolated by laser microdissection (LMD) from human atherosclerotic and pre-153 
atherosclerotic coronaries have been studied [7]. This selective approach is also considered 154 
essential for studying the different cell populations or the cellular/extracellular components 155 
to better understand their contribution in the pathogenesis of the disease [29]. Finally, 156 
tissue secretome represents an alternative sample source. Tissue explants directly obtained 157 
from healthy and diseased arteries are cultured and their supernatant which is enriched in 158 
secreted proteins, is used for proteomics analysis [30].  159 
3.2 Sub-cellular proteomes 160 
The majority of the sub-cellular studies in the field of cardiovascular proteomics focus on the 161 
analysis of the mitochondrial [31] and extracellular matrix (ECM) proteomes [32]. Other sub-162 
cellular proteomes, including myofilaments [33], sacromere [34] and proteasomes [35] have 163 
been less extensively investigated. Isolation of the sub-cellular fractions in general involves 164 
application of differential centrifugation, immune-based isolation, and membrane protein 165 
enrichment [36] methods.  166 
3.2.1 ECM 167 
The ECM is involved in a broad spectrum of signaling events during growth, differentiation, 168 
injury, and remodeling [37]. Technical challenges are the insolubility and extensive PTMs of 169 
the ECM proteins, and their low abundance (~1% of proteome) compared to the highly 170 
abundant cellular or plasma proteins. ECM enrichment strategies via decellularization, 171 
sequential solubilization and extraction of ECM constituents have been applied to overcome 172 
these obstacles [38-41]. Of note, Didangelos et al, through the application of these 173 
procedures, analyzed the ECM proteome in human aortic samples [39] and identified 103 174 
ECM proteins with the one third of them not previously described in the context of vascular 175 
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tissue proteomics. The same group characterized ECM remodeling in abdominal aortic 176 
aneurysms [42]. ECM remodeling has also been described in HF and cardiac fibrosis [32,43].  177 
3.2.2 Mitochondria 178 
In a healthy cardiomyocyte, mitochondria represent ~40% of the volume. Mitochondria are 179 
essential for providing energy (for the contraction of the muscle), but also for regulating 180 
programmed cell death. Accumulating evidence supports that CVD progression is associated 181 
with changes in mitochondria structure and function [44,45]. An increasing number of 182 
studies focus on the characterization of alterations of the mitochondrial proteome in CVD 183 
[31], including pressure overload-induced HF [46], atrial fibrillation (AF) [47] and type I [48] 184 
and type II diabetic heart [49]. Goudarzi et al., performed LC-MS/MS analysis of isolated 185 
mitochondrial enriched fractions from right atrial tissues and identified 32 differentially 186 
expressed proteins in patients with AF compared to non-AF patients [47]. Other studies have 187 
also tried to analyze the effect of oxidative stress on cardiac mitochondrial protein dynamics 188 
by using in vivo models [50].  189 
3.3 Biological fluids 190 
Biological fluids, such as serum, plasma and urine, represent the ideal specimen for 191 
biomarker detection because they are easily accessible. Since urine and plasma account for 192 
the vast majority of biomarker studies, they will be reviewed extensively in the section on 193 
biomarkers (below).  194 
3.4 Circulating cells and extracellular vesicles 195 
Proteome analysis of circulating cells such as monocytes, platelets and endothelial cells may 196 
provide a better understanding of the involvement of these cells in CVD and enable 197 
identification of disease associated biomarkers. Monocytes play important roles in 198 
inflammation and atherosclerosis and therefore their proteomic profiling may provide novel 199 
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insights into their function, as indicated from recent studies [51,52]. Additionally, proteomic 200 
analyses of platelets in CVD [60,61], as well as circulating endothelial cells (CECs) and the 201 
endothelial progenitor cells (EPCs) in patients with ACS have also been described [53].  202 
Plasma microvesicles (including microparticles and exosomes) are advocated as source of 203 
vascular-specific disease biomarkers. Membrane microvesicles, mainly released from 204 
activated platelets into the circulation, represent an important mode of intercellular 205 
communication and their number is increased in patients with acute coronary syndromes 206 
[54]. Comprehensive proteomic analysis of the plaque microparticles derived from human 207 
atherosclerotic lesions revealed that they derived primarily from leukocytes and are 208 
implicated in inflammation [55]. 209 
4. PTMs 210 
Protein PTMs, including phosphorylation, ubiquitylation, acetylation, N- and O-linked 211 
glycosylation, and methylation, are key regulators of the protein conformation, stability and 212 
activity [56].  213 
Protein phosphorylation is critical to myocardial function since it underpins cellular 214 
processes associated with energy metabolism, signal transduction and contractile function of 215 
the myocyte [57]. Thus, phosphorylation is the most commonly described PTM in the cardiac 216 
proteome [58,59]. Changes in the abundance of 25 phosphoproteins have been previously 217 
identified in hypertensive cardiac remodeling through the application of 2D-DIGE on 218 
phosphoenriched proteins [60]. Among them, myofilament proteins such as Alpha-219 
tropomyosin and Myosin; mitochondrial proteins such as Pyruvate dehydrogenase A; 220 
phosphatases such as Protein phosphatase 2A; other proteins including Proteasome subunits 221 
α-type 3 and β type 7 and Eukaryotic translation initiation factor 1A, were included. 222 
Employing top-down MS-based quantitative proteomics, the phosphorylation of cardiac 223 
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Troponin I has been identified as a biomarker for congestive heart failure (CHF) [61], as 224 
described below.  225 
5. Biomarkers currently applied 226 
Biomarkers must provide accurate and reliable information about disease in order to aid in 227 
prognosis, diagnosis, or therapy monitoring. Currently, there are four biomarkers 228 
recommended for clinical use in CVD (summarized in Figure 3): 1) Cardiac Troponin T and 229 
cardiac Troponin I [62] are used for the diagnosis of acute coronary syndrome (ACS) and MI, 230 
while elevated plasma levels of troponin T represent the gold standard approach to detect 231 
MI [63] with a high predictive value [64]. The development of high-sensitivity assays for 232 
Troponin I and T has improved the diagnostic sensitivity for acute myocardial infarction 233 
(AMI) [65]. 2) B-type natriuretic peptide (BNP) and its N-terminal form are employed to 234 
detect congestive heart failure [66]. Circulating concentrations of BNP reveal strong 235 
associations with CVD risk under a range of different clinical conditions. 3) C-reactive protein 236 
(CRP) [67,68] and D-dimer [69], are inflammatory markers associated with ischemic heart 237 
disease. 4) Apolipoprotein A-I , the major protein component of HDL, is an excellent risk 238 
predictor for CVD related to the metabolism of high-density lipoprotein (HDL) [70]. While 239 
these biomarkers have clearly demonstrated value in multiple studies, a significant limitation 240 
appears in that they detect mainly late stage of CVD.  241 
In the following section we present an overview of potential biomarkers for CVD that have 242 
been recently identified using proteomic technologies, categorized by the biological source 243 
investigated, and summarized in the respective tables. 244 
 245 
6. Proteomic biomarkers in CVD 246 
6.1 Tissue 247 
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The affected tissue certainly holds the most relevant information on molecular pathology, 248 
enabling identifying potential therapeutic targets. Tissue is not easily accessible, and 249 
certainly cannot be assessed for routine diagnosis. However, results from tissue proteomics 250 
may enable generating hypotheses on circulating biomarkers, which can subsequently be 251 
tested [71]. Several studies therefore focused on tissue, as summarized in Table 1. 252 
6.1.1 Arterial Tissue 253 
Atherosclerotic plaque may hold proteomic information on molecular alterations that 254 
discriminate patients with adverse cardiovascular events from those that remain stable 255 
during follow-up. De Kleijn et al. investigated the carotid atherosclerotic plaque proteome by 256 
MS in relation to outcome, during a 3-year follow-up. With this approach, Osteopontin 257 
(OPN) was identified as a potential instable plaque biomarker and subsequently validated in 258 
femoral plaque samples, indicating predictive value independent of plaque localization. The 259 
authors concluded that high levels of OPN from atherosclerotic plaques could be prognostic 260 
of the occurrence of cardiovascular events [72]. Hao et al. fractionated proteins from human 261 
carotid atherosclerotic plaques using Electrostatic Repulsion-Hydrophilic Interaction 262 
Chromatography followed by offline LC-MS/MS. Several previously undetected low-263 
abundant proteins with important functions in atherosclerosis, such as TGF-β, interleukins 264 
and other growth factors were identified. The authors highlighted three proteins; 265 
Myeloperoxidase (MPO), Fibrinogen gamma chain (FGG) and Fibrinogen beta chain (FGB), as 266 
potential CVD biomarkers [73].  267 
To overcome the barrier of early studies using whole tissue proteome, LMD of the intimal 268 
layer from human atherosclerotic and pre-atherosclerotic coronaries was used in 269 
combination with a 2D-DIGE approach. This study identified 13 proteins, with three of them, 270 
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Annexin 4 (ANXA4), Myosin regulatory light 2 smooth muscle isoform (MYL9) and Ferritin 271 
light chain (FTL), representing novel findings in the atherosclerotic coronary intima [7]. 272 
6.1.2 Cardiac tissue 273 
The number of proteomic studies using human heart tissue samples is low, due to obvious 274 
difficulties in sampling. One study performed by Kakimoto et al. included the proteomic 275 
analysis of human cardiac tissue obtained from cases of sudden death due to AMI. In this 276 
study, using LC-MS/MS, reduced levels of the sarcoplasmic protein, Sorbin and SH3 domain-277 
containing protein 2 (SORBS2) was detected in the infarcted myocardia. SORBS2 levels were 278 
also found increased in serum of AMI patients, indicating its potential to be used as a 279 
biomarker [74]. 280 
Aiming at identification of novel biomarkers for early detection of CHF, Zhang et al., 281 
characterized the PTMs associated with disease progression. Top-down quantitative 282 
proteomics using affinity chromatography and high resolution MS was applied onto human 283 
heart tissue samples. Phosphorylation of cardiac Troponin I was identified as a candidate 284 
biomarker for detection of CHF [61]. 285 
6.1.3 Atherosclerotic vulnerable plaques 286 
Aiming at identifying circulating biomarkers derived from atherosclerotic vulnerable plaques 287 
that could predict adverse cardiovascular events, Malaud et al. performed protein 288 
enrichment followed by 2DE in protein extracts obtained from human fibrotic and 289 
hemorrhagic carotid atherosclerotic plaques. Several proteins were found to be differentially 290 
released by vulnerable hemorrhagic human carotid plaques when compared with stable 291 
fibrotic plaques. The authors suggest that combinations of the circulating biomarkers 292 
Calponin-1 (CNN1), IL-8, DJ-1 (PARK7), Vascular endothelial growth factor (VEGF) and PCPE-1 293 
(PCOLCE) could be used for coronary patient stratification [75]. 294 
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6.1.4 Thrombus 295 
Intra-luminal thrombus (ILT) secretions from AAA patients were analyzed by LC–MS/MS and 296 
two thrombus associated proteins, serum Thrombospondin-1 (TSP-1) and Clusterin (CLU), 297 
were identified at reduced levels in circulation of patients with AAA compared to non 298 
aneurismal controls [76]. Targeting the identification of biomarkers in AAA progression, 299 
Martinez-Pinna et al. analyzed the proteins released by the different layers 300 
(luminal/abluminal) of the ILT by 2D-DIGE. This analysis identified Peroxiredoxin-1 (PRDX1) 301 
as prominently released by the luminal layer of the ILT. PRDX1 levels were further analyzed 302 
by ELISA in the serum of patients with AAA and were found increased compared to the 303 
healthy individuals. A significant positive correlation between PRDX1 serum levels with AAA 304 
size and growth rate had an additive predictive value in AAA, indicating PRDX1 as a potential 305 
biomarker for AAA progression [8]. The same group analyzed the tissue-conditioned media 306 
from patients with AAA by LC-MS/MS and identified that decreased levels and activity of 307 
systemic C3 in advanced AAA stages are associated with AAA evolution [77]. In another 308 
study, emphasis was given to the identification of peptides and low-molecular-weight 309 
proteins released by the different layers of abdominal aortic aneurysm thrombus. By 310 
employing SELDI-TOF mass spectrometry, LVV- Hemorphin7 (H7) and VV-H7, both generated 311 
from hemoglobin proteolysis, were found more abundantly released by recently formed 312 
luminal layer of AAA thrombus relative to intermediate and abluminal older layers. The 313 
levels of the H7 peptides were also found increased in the serum of AAA patients compared 314 
to controls and were positively correlated with the AAA diameter and thrombus volume. 315 
These peptides may be used as biological markers of pathological vascular remodeling [78].  316 
The proteomic profiling of the coronary thrombus from MI patients has been recently 317 
performed using three different proteomic approaches: 2DE-MALDI MS/MS, 1DE- LC-MALDI-318 
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MS/MS or 1DE-LC-ESI-MS/MS. Co-expression of 5 focal adhesion proteins [Fermitin homolog 319 
3 (FERMT3), Thrombospondin-1 (THBS1), Myosin-9 (MYH9), Beta parvin (PARVB) and Ras-320 
related protein Rap-1b (RAP1B)] with CD41 (ITGA2B) was found to be potentially implicated 321 
in platelet activation during thrombus formation. Additionally, Death-inducer obliterator 1a 322 
(DIDO1), was found up-regulated in the plasma of patients and was suggested as potential 323 
biomarker of thrombosis [28]. In an effort to better understand the characteristics of 324 
coronary thrombus, Ramaiola et al. employed 2DE-MS and found that the aged ischemic 325 
thrombi T6 (more than 6h of evolution) in STEMI patients are characterized by reduced 326 
levels of Profilin-1 (PFN-1) compared to T3 (thrombus of less than 3h of evolution) likely due 327 
to its release in the peripheral circulation since its levels were found by ELISA significantly 328 
increased in coronary and systemic blood in T6 patients compared to T3 [79].  329 
6.1.5 Tissue secretome 330 
Several proteomics approaches aimed at elucidating the molecular mechanisms involved in 331 
plaque formation to identify potential biomarkers for early diagnosis of disease. The 332 
advantage of using tissue secretome instead of whole tissue proteome is that secretome 333 
may reflect the in vivo condition with reduced complexity. Early studies revealed a significant 334 
reduction of soluble TNF-like weak inducer of apoptosis (sTWEAK) in carotid plaque 335 
supernatants compared to normal mammary endartery conditioned media [80]. The same 336 
trend was also described in chronic stable HF [81], peripheral artery disease (PAD) [82], AAAs 337 
[83] and CAD [84]. The potential of sTWEAK as prognostic biomarker in CVD has also been 338 
suggested [85,86].  339 
The carotid plaque secretome has also been studied using LC-MS approaches. Among the 31 340 
differentially secreted proteins from plaques, extracellular and intracellular proteins such as 341 
Thrombospondin-1 (THBS1), Vitamin D binding protein (GC), and Vinculin (VCL) were 342 
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identified. A significantly higher concentration of THBS1 and GC was confirmed in 343 
atherosclerotic subjects in comparison to controls [87].  344 
In an attempt to identify novel circulating CAD biomarkers Reiser et al, analyzed the 345 
secretome derived from atherosclerotic plaques of carotid/iliac arteries and control arterial 346 
tissue by antibody phage display followed by MS. In parallel, gene expression analysis of the 347 
coronary thrombi versus peripheral blood mononuclear cells was performed. Integrating the 348 
data from the proteomic and gene expression studies enabled identification of Fatty acid-349 
binding protein 4 (FABP4) as a candidate biomarker for CAD. FABP4 was found in the plaque 350 
but not in the control secretome and its expression was higher in thrombi than in peripheral 351 
blood mononuclear cells. FABP4 failed to serve either as a clinically relevant diagnostic 352 
marker in stable CAD and ACS or as prognostic biomarker in an asymptomatic population. 353 
However, FABP4 could identify ACS patients at risk for adverse cerebrovascular or 354 
cardiovascular events and therefore the authors concluded that circulating FABP4 may be 355 
utilized as a prognostic biomarker in risk stratification of ACS patients [88].  356 
 357 
6.2 Plasma and Serum biomarkers 358 
Plasma has been the main target specimen of biomarker research in cardiovascular disease, 359 
owed to its availability, and proximity to the affected organ (vessel or heart). The results 360 
obtained are summarized in Table 2. Darde et al. [89], investigated the plasma proteome 361 
from patients, healthy controls, and stable CAD patients using immunodepletion of the six 362 
most abundant proteins, and 2DE and 2D-DIGE analysis. Along with proteins previously 363 
associated with ACS, four novel proteins associated with the pathology [Alpha-1- B-364 
glycoprotein (A1BG), Hakata antigen (FCN3), Tetranectin (CLEC3B) and Tropomyosin 4 365 
(TPM4)] were identified [89]. More recently, Kristensen et al., employed plasma-based 366 
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quantitative proteomics for the analysis of four well-phenotyped patient cohorts: individuals 367 
1) without cardiovascular symptoms and without the presence of coronary calcium, 2) 368 
without cardiovascular symptoms but with high amounts of coronary calcium, 3) operated 369 
because of atherosclerotic diseases, and 4) with ACS [90]. Through a 5-plex SRM-MS assay, 370 
statistically significant increased levels of the cytoskeletal protein Vinculin (VCL) were 371 
verified, along with other known risk markers of CVD such as CRP, Serum amyloid protein A 372 
(SAA1) and Apolipoprotein-A (APOA1) in the ACS group [90]. Lepedda et al., performed a 373 
comprehensive analysis of the differentially expressed Apolipoprotein component of plasma 374 
VLDL, LDL and HDL from patients undergoing carotid endarterectomy compared to healthy 375 
individuals. A panel of twenty three proteins was identified through the application of 2DE 376 
coupled with Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) MS 377 
analysis. Among them, Acute-phase serum amyloid A protein (SAA1) was over-expressed in 378 
all lipoprotein fractions indicating a potential association with the presence of advanced 379 
carotid lesions [91]. Recently, a novel targeted proteomics approach, based on the proximity 380 
extension assay proteomics chip, allowed the discovery of associations of Osteoprotegerin 381 
(TNFRSF11B), Growth hormone (GH1), Tumor necrosis factor ligand superfamily member 14 382 
(TNFSF14) and Renin (REN) with plaque occurrence, independently of each other and 383 
traditional CVD risk factors [24]. Cheng et al. selected 13 candidate biomarkers possibly 384 
associated with plaque vulnerability and investigated their prognostic value in CAD patients 385 
in a nested-case-control study involving 768 patients undergoing coronary angiography. 386 
Increased plasma levels of circulating Osteoglycin (OGN) and Neutrophil gelatinase-387 
associated lipocalin/matrix metalloproteinase 9 (NGAL/MMP9) were independently 388 
predictive for occurrence of major adverse cardiovascular event (MACE) within 1 year after 389 
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coronary angiography. Combining these two proteins with convential risk factors 390 
significantly improved risk reclassification [92].  391 
AAA is associated with inflammatory responses with cytokines as important mediators. By 392 
analyzing the cytokine profile in plasma of patients with AAA via a protein array approach, 393 
elevated Insulin Like Growth Factor Binding Protein 1 (IGFBP1) was identified as a potential 394 
novel disease biomarker [25]. Burillo et al. performed differential quantitative proteome 395 
analysis using iTRAQ labeling and nano-LC-MS/MS of plasma proteins from patients at 396 
different AAA stages of evolution [small (aortic size 3-5cm) vs large AAA (aortic size > 5cm)]. 397 
Among the differentially expressed proteins APOA1 was identified significantly reduced in 398 
patients with large AAA compared to small AAA. Furthermore, a strong correlation of APOA1 399 
levels with HDL-Cholesterol (HDL-C) concentration as well as with aortic size and thrombus 400 
volume (negative correlations) were also observed. The authors concluded that the systemic 401 
levels of APOA1/HDL-C are negatively associated with AAA progression [93]. 402 
To identify novel plasma protein biomarkers that could improve risk assessment for MI and 403 
atherosclerotic cardiovascular disease (ASCVD), Yin et al., compared plasma proteins in 404 
patients and controls through the application of a discovery-validation pipeline. In the 405 
discovery phase, plasma proteins in MI case-control pairs were analyzed using iTRAQ with 406 
multidimensional LC-MS/MS (discovery MS). The most promising protein biomarkers were 407 
subsequently chosen for the validation phase where plasma proteins from ASCVD case-408 
control pairs were analyzed using MRM. This approach enabled identification of single- and 409 
multiple-marker protein panels significantly associated with CVD, the latter including 4 410 
proteins in combination [α-1-acid glycoprotein 1 (ORM1), Paraoxonase 1 (PON1), Tetranectin 411 
(CLEC3B), and CD5 antigen-like (CD5L)] [94].  412 
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Comparative proteome analysis was performed in depleted plasma protein samples from 413 
patients with AMI, unstable angina pectoris (UAP), stable angina pectoris (SAP) and control 414 
subjects, using 2D SDS-PAGE followed by nanoLC-MS/MS analysis. Although two of the 415 
identified proteins, Alpha-1 microglobulin (AMBP) and Vitamin D-binding protein (GC) failed 416 
as suitable CVD markers, Apolipoprotein-A1 (APOA1) isoforms detected by 1D and 2D SDS-417 
PAGE only in patients groups were presented as possible biomarkers for CVD [95]. In an 418 
effort to identify prognostic biomarkers for AMI, proteome analysis of depleted plasma 419 
samples from AMI patients was performed by 2D-DIGE. A 1-year follow-up was used to 420 
identify patients with heart failure and these data were used for the hierarchical clustering 421 
of the proteomic findings. Among the 22 differentially expressed proteins were isoforms of 422 
Haptoglobin (HP). Their distinct patterns were associated with stratification of the disease 423 
and HP plasma levels predicted the occurrence of HF at 1-year [96].  424 
Identification of plasma biomarkers for early detection of myocardial injury is an active 425 
research field; one study applied integrated proteomic technologies in a human model that 426 
faithfully reproduces clinical aspects of spontaneous MI [patients undergoing a therapeutic, 427 
planned myocardial infarction (PMI) for treatment of hypertrophic cardiomyopathy]. 428 
Coherent, MS-intensive pipeline, including high-performance LC-MS/MS, accurate inclusion 429 
mass screening (AIMS), stable isotope dilution (SID)-MRM-MS and immunoassays were 430 
employed which collectively revealed a panel of candidate biomarkers that may be specific 431 
to MI. This included previously known cardiovascular biomarkers such as Creatine kinase 432 
MB, Fatty Acid Binding Protein (FABP) and Myeloperoxidase (MPO) and novel candidates 433 
such as Aortic Carboxypeptidase-Like Protein ACLP1, Four And A Half LIM Domains 1 (FHL1), 434 
Myosin Light Chain 3 (MYL3) and Tropomyosin 1 (TPM1) [97]. Applying an aptamer-based 435 
platform in patients with planned and spontaneous MI, 79 candidate infarct markers were 436 
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detected, including previously known markers (eg. Troponin I and Creatinine kinase MB) and 437 
novel candidates [eg. Fibroblast growth factor 18 (FGF18) and Interleukin-11 (IL11)]. This 438 
study allowed also the identification of low abundance cytokines and cell-surface proteins in 439 
association to disease, not previously reported [27].  440 
Analyzing plasma samples from 90 CVD patients with a highly multiplexed MRM-based 441 
assay, Domanski et al assessed 67 putative CVD plasma biomarkers involved in coagulation 442 
and thrombolysis pathways, acute-phase reaction, inflammation as well as lipoprotein 443 
formation [19]. An MRM assay panel was also developed for the detection of ischemic heart 444 
disease and MI, based on 11 proteins with association to CVDs. Comparative analysis of 445 
plasma samples obtained from patients with ST-segment elevation MI and chest pain due to 446 
other causes identified increased levels of Apolipoprotein C1 (APOC1), Apolipoprotein C2 447 
(APOC2) and Apolipoprotein E (APOE) in the former, rising the interest for further studying 448 
the role of these apolipoproteins in the pathophysiology of AMI [98]. 449 
Plasma proteomics also enables identification of potential biomarkers for acute 450 
decompensated heart failure (ADHF). Employing a discovery platform where depleted 451 
plasma protein samples from ADHF patients were analyzed by nano LC-MALDI-TOF/TOF and 452 
a verification platform based on nano LC-SRM analysis, Mebazaa et al. identified increased 453 
levels of Quiescin Q6 (QSOX1) as a novel biomarker further validated in human studies and 454 
also in animal models. Combination of QSOX1 to the gold standard biomarker BNP improved 455 
diagnostic accuracy and specificity for ADHF diagnosis [99].  456 
To gain insight into the pathology of valvular aortic stenosis (AS), plasma proteins from AS 457 
patients and controls were analyzed by 2D-DIGE followed by MS. In this analysis, crude and 458 
pre-fractionated plasma either depleted or equalized was analyzed leading to the 459 
identification of 36 differentially expressed proteins in AS. These were further clustered into 460 
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functional groups including protease inhibitors and proteases, blood homeostasis and 461 
coagulation, inflammation and immune response, lipid metabolism and transport and others 462 
[100]. 463 
Degraba et al. investigated the proteomic signature of serum of patients with carotid artery 464 
disease compared to healthy individuals in order to identify protein biomarkers associated 465 
with increased atherosclerotic risk. Using 2D-DIGE in fractionated serum, decreased levels of 466 
α(1)-antitrypsin (A1AT), Haptoglobin (HP) and Vitamin D binding protein (GC) and increased 467 
levels of α(2)-glycoprotein precursor (AZGP1) in the subset of patients with symptomatic 468 
carotid atherosclerosis were detected [101]. Targeting to correlate CAD imaging findings 469 
with circulating biomarker expression, proteome analysis of the serum of 66 patients with 470 
stable or unstable angina and AMI after 3 and 6 months follow up was performed. Pro-471 
inflammatory markers [6C Kine (CCL21), CTAK (CCL27), MIG (CXCL9) and Platelet Factor 4 472 
(PF4)], pro-coagulable markers [D-dimer (FDP), Platelet Factor 4 (PF4) and Hepatocyte 473 
Growth Factor (HGF)] and marker of shear stress and remodeling [Follistatin (FST)] all 474 
decreased over time whereas anti-apoptotic markers [PAI-10 (CXCL10) and I-309 (CCL1) 475 
chemokine] were up-regulated [26]. Han et al. employed 2DE coupled with MS to 476 
characterize protein expression patterns in the serum of CAD patients. Serum cyclin-477 
dependent kinase 9 (CDK9) was found elevated in the serum with a concomitant increase in 478 
monocytes and artery plaque samples of CAD patients. Further analysis indicated CDK9 as a 479 
potential biomarker of atherosclerotic inflammation [102].  480 
In an effort to identify biomarkers for ventricular dysfunction and HF, Watson et al. analyzed 481 
the coronary sinus serum from asymptomatic, hypertensive patients. By employing 2DE, 482 
they detected increased levels of Leucine-rich α2-glycoprotein (LRG) in the serum of the 483 
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patients with increased BNP. Further investigation in an independent cohort demonstrated 484 
significant association of LRG with HF, independent of BNP [103]. 485 
Cubedo et al. compared the serum proteome of new-onset AMI patients with healthy 486 
individuals to identify biomarkers of early stages of AMI. Applying 2DE followed by MALDI-487 
TOF, decreased levels of Apolipoprotein J/clusterin (APOJ) within the first 6h after the onset 488 
of AMI accompanied by alterations in its glycosylation pattern were detected [104]. 489 
Following the same approach, the same group compared the serum proteome from early 490 
and late phase AMI patients. Late phase AMI was associated with a decrease in immune 491 
response-inflammation proteins [alpha-1B-glycoprotein (A1BG), Fetuin-A (AHSG), Complex-492 
forming glycoprotein HC (AMBP), Complement C1r Subcomponent (C1R), Complement 493 
Component 3 (C3) and Factor-B (CFB)] and an increase in the levels of Serum amyloid P-494 
component (SAP) in comparison to early AMI [105]. In a more recent study, the same group 495 
also found that decreased serum Retinol Binding Protein 4 (RBP4) levels are implicated in 496 
acute new-onset MI in male patients [106]. 497 
The detection of novel serum biomarkers could be also very helpful for both diagnosis and 498 
development of novel treatment modalities for transient ischemic attacks (TIA). To this end, 499 
George et al., attempted to identify novel serum TIA biomarkers through the application of 500 
mass spectrometry-based proteomics. The study highlighted Platelet basic protein (PBP) as a 501 
candidate TIA/minor stroke serum biomarker [107].  502 
To identify biomarkers for acute aortic dissection (AAD), Gu et al., compared serum samples 503 
from AAD patients, AMI patients and healthy individuals using iTRAQ MS proteomics. 504 
Analysis of the differentially expressed proteins identified increased levels of Lumican (LUM) 505 
as a potential AAD-related serum marker [108].  506 
 507 
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6.3 Urine 508 
Urinary proteomics benefits from the considerable stability of the urinary proteome and the 509 
establishment of large scientific networks [109], and hence has been applied in multiple 510 
studies also in the context of CVD (Table 3). Hou et al. applied 2D-DIGE for the analysis of 511 
urinary protein extracts of CHF patients and healthy donors. Among the twenty detected 512 
differentially expressed proteins, Orosomucoid 1 (ORM1) was selected based on 513 
bioinformatics analysis for further verification by Western blot analysis and ELISA. The 514 
authors conclude that increased levels of ORM1 may be used as potential novel urinary 515 
biomarker for the early detection of CHF [110]. 516 
Applying 1DE-LC-MS/MS, Lee et al. detected increased levels of monocyte antigen CD14 in 517 
the urine samples from CAD patients compared to controls. Furthermore, the proportion of 518 
CD14+ monocytes was found elevated in CAD patients compared to controls. The authors 519 
suggested that the increased release of CD14 in urine coupled with the elevated number of 520 
CD14+ monocytes in CAD patients may be associated to CAD severity [111].  521 
Recently, efforts have been made towards employing multiple proteomic biomarkers, in 522 
order to more comprehensively depict complex disease pathophysiology. To this end, Delles 523 
et al., analyzed urine samples from 623 individuals with and without CAD by CE-MS. A panel 524 
of 238 CAD-specific urinary polypeptides with good sensitivity and specificity for CAD 525 
diagnosis was reported. The identified discriminatory polypeptides included fragments of 526 
alpha-1-antitrypsin (SERPINA1), Collagen types 1 and 3, Granin-like neuroendocrine peptide 527 
precursor (PCSK1N), Membrane-associated progesterone receptor component 1 (PGRMC1), 528 
Sodium/potassium-transporting ATPase gamma chain (FXYD2) and Fibrinogen-alpha chain 529 
(FGA) [13]. The same group, by following the same approach, recently demonstrated the 530 
value of the CAD238 panel as predictor of coronary events in asymptomatic subjects with 531 
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hypertensive atherosclerotic cardiovascular disease (HACVD) [112] and in the diagnosis of 532 
stable angina [113].  533 
The development of urinary biomarker panels has also been applied targeting early 534 
detection of ischemic stroke specifically reliable detection of minor ischemic stroke or TIA, 535 
especially in cases of inconclusive brain imaging [14]. To this end, the urinary proteome of 536 
patients with acute stroke or TIA and controls with elevated cardiovascular risk was explored 537 
through the application of CE-MS. Candidate biomarkers were further identified following 538 
LC-MS/MS. A biomarker-based classifiers was developed that enabled differentiating 539 
between patients with acute stroke or TIA and controls [14]. Peptides of the discriminatory 540 
panels included FXYD domain-containing ion transport regulator 4 (FXYD4), Inter-alpha-541 
trypsin inhibitor heavy chain H4 (ITIH4), Uromodulin (UMOD), Polymeric-immunoglobulin 542 
receptor (PIGR) and Collagen fragments.  543 
A pilot study, using CE-MS based urine proteome analysis, enabled identification of a vast 544 
array (103) of HFrEF-related urinary peptide biomarkers which mainly included fragments of 545 
fibrillar type I and III Collagen but also Fibrinogen beta (FGB) and alpha-1-antitrypsin 546 
(SERPINA1) peptides [15]. This opens the possibility of early diagnosis of HFrEF even before 547 
the disease progresses to an overt symptomatic stage. Application of the same technology 548 
identified a set of HFrEF-specific urinary peptide biomarkers on a background of chronic 549 
kidney disease (CKD). Consistent with the previous study, the majority of sequenced 550 
peptides were fragments of Collagen type I and III [114]. 551 
Urinary proteome-based classifiers have been assessed for their value in the early detection 552 
of asymptomatic left ventricular diastolic dysfunction (LVDD) in hypertensive patients. In one 553 
study, a set of urinary polypeptides was identified by CE-MS to distinguish hypertensive 554 
patients with overt HF from healthy controls: HF1 and HF2 are classifiers based on 85 and 555 
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671 urinary peptides, respectively, and were generated to distinguish between patients with 556 
LVDD and controls [115]. These classifiers were further assessed in a population study by 557 
analyzing the urinary proteome by CE-MS [116]. The same group, in a subsequent study 558 
investigated whether HF1 classifier predicts cardiovascular end points in a population of 791 559 
randomly recruited normal subjects over a 5 year follow-up period. The urinary proteomic 560 
signature was found to predict CVD incidence at higher accuracy than systolic pressure [117]. 561 
While the advantage of CE-MS in the management of CVD is very promising and attributed 562 
not only to the robustness of the technique (i.e. inter-laboratory variability, stability, 563 
interference with drugs) [118], but also to its multiple applications in patient management 564 
and drug development [119], it has a low urine loading capacity and is only suitable for small 565 
proteins (< 20 kDa) [119]. CE-MS identifies naturally occurring peptides with distinct c- and 566 
n-terminal that enables a specific evaluation of the disease pathology. Frequently a highly 567 
significant change in abundance of specific collagen fragments is detected. The most likely 568 
hypothesis today is that these specific peptides reflect altered protease activity which has a 569 
specific impact on collagen (as well as likely multiple other proteins), and which is associated 570 
with several pathologies [120].    571 
 572 
6.4 Circulating Cells 573 
Circulating cells and vesicles may play a major role in CVD pathophysiology. Several 574 
proteomics studies targeting these specimens have been reported, summarized in Table 4. 575 
Polymorphonuclear neutrophils (PMNs) play a key role in the pathophysiology of AAA 576 
progression [121,122], and as such, Ramos-Mozo et al., comparatively analyzed their 577 
proteome in AAA patients and controls. Using 2D-DIGE-MALDI MS, they identified decreased 578 
26 
 
levels of Catalase (CAT) further confirmed by an apparent decrease activity of Catalase in 579 
circulating PMNs and plasma in AAA patients [123]. 580 
To gain insight into the association of circulating cells with coronary atherosclerosis, 581 
Bleijerveld et al. performed in-depth proteomic profiling of granulocytes in a cohort of 582 
patients suffering from chronic (sub)total coronary occlusion in comparison to matched 583 
control patients. Using stable isotope peptide labeling and 2DE LC-MS/MS, 57 candidate 584 
biomarker proteins were identified including Bactericidal/permeability-increasing protein 585 
(BPI), Ficolin-1 (FCN1), Charcot−Leyden crystal protein (CLC), Eosinophil granule major basic 586 
protein (MBP) and Eosinophil-derived neurotoxin (EDN). Following further verification in an 587 
independent cohort by label-free proteome analysis, the down-regulation of 588 
Bactericidal/permeability-increasing protein (BPI) in circulating granulocytes was proposed 589 
as a promising biomarker for severe atherosclerotic coronary stenosis [124]. 590 
To investigate the profiles of macrophages from AAA patients and peripheral arterial 591 
occlusion (PAO) patients without AAA, transcriptomics and proteomics approaches were 592 
followed. Differentially expressed proteins were identified through the application of 2D-593 
DIGE followed by MALDI TOF. An antibody protein array was used to validate selected 594 
proteins found (or predicted) to be differentially expressed in macrophages and plasma 595 
based on the transcriptomic and proteomic analysis. TIMP-3, ADAMTS5, and ADAMTS8 were 596 
found differentially expressed between the macrophages and plasma of AAA and PAO 597 
patients [125].  598 
Changes in the proteome profile of circulating endothelial cells (CECs) and EPCs have also 599 
been described in ACS. CECs and EPCs were isolated by flow cytometry from blood obtained 600 
from ACS patients and control subjects. Proteome analysis by LC-MS/MS identified 601 
differences in EPC and CEC proteins between control and ACS patients, predicted to 602 
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segregate into 6 molecular pathways (5HT4 type receptor mediated signaling pathway, 5HT3 603 
type receptor mediated signaling pathway, 5HT1 type receptor mediated signaling pathway, 604 
Adrenaline and noradrenaline biosynthesis and Heterotrimeric G-protein signaling pathway-605 
rod outer segment phototransduction exclusively represented in ACS). Although this study 606 
indicated the potential of CEC and EPC to reflect CVD, the development of a ‘’gold standard’’ 607 
protocol for their isolation is imperative for their further implementation in biomarker 608 
development and diagnostics [53].  609 
 610 
6.5 Extracellular vesicles 611 
Membrane microvesicles (MVs) are released into the circulation from activated cells, such as 612 
platelets, they mediate intercellular communication, and their number is increased in 613 
patients with ACS [126]. To develop a unique panel of proteins discriminating patients with 614 
STEMI from stable CAD controls, Velez et al. performed comparative proteome analysis in 615 
plasma MVs based on 2D-DIGE MS. An up-regulation of α2-macroglobulin isoforms, 616 
Fibrinogen, and Viperin (RSAD2) was detected in MVs from STEMI patients [54]. 617 
In a recent study by Cheow et al. the proteome profile of plasma EVs derived from patients 618 
with MI in comparison to EVs from patients with stable angina was analyzed by LC-MS/MS. A 619 
biomarker panel for MI detection was developed, comprising of six up-regulated proteins: 620 
Complement C1q subcomponent subunit A (C1QA) and Complement C5 (C5), both 621 
associated with complement activation; Apoliporotein D (APOD) and Apolipoprotein C-III 622 
(APOCC3), implicated in lipoprotein metabolism; and Platelet glycoprotein Ib alpha chain 623 
(GP1BA) and Platelet basic protein (PPBP), both related to platelet activation [127]. 624 
Martinez-Pinna et al. employed label-free LC-MS for the quantitative proteome analysis of 625 
plasma-derived microvesicles (exosomes and microparticles) from AAA patients and control 626 
28 
 
subjects. Differentially expressed proteins not previously associated with AAA were 627 
detected. Among the proteins upregulated in exosomes from AAA patients were Ferritin 628 
light chain (FTL), C-reactive protein (CRP) and Platelet factor 4 (PLF4) whereas Dermcidin 629 
(DCD), Annexin A2 (ANXA2) and Oncoprotein-induced transcript 3 protein (OIT3) increased in 630 
microparticles of AAA patients [128]. 631 
The proteome of plasma-microparticles has also been investigated in DVT through the 632 
application of 2D MALDI MS/MS. Galectin-3 binding protein precursor (LGALS3BP) and 633 
Alpha-2 macroglobulin (A2M] were significantly enriched in DVT patients whereas among 634 
others Alpha-1-antitrypsin precursor (SERPINA1), Histidine-rich glycoprotein precursor 635 
(HRG), Hemopexin precursor (HPX), Fibrinogen beta chain precursor (FGB), Isoform Gamma-636 
B of Fibrinogen gamma chain precursor (FGG), Fibronectin 1 isoform 4 preproprotein (FN1), 637 
and Rheumatoid factor RF-IP16 (RF) were reduced in DVT versus controls [129]. 638 
 639 
6.6 Platelets 640 
Banfi et al. compared the proteome of isolated platelets from patients with stable angina or 641 
non-ST elevation ACS compared to control subjects with no history of CAD, using 2DE-MS. Six 642 
differentially expressed proteins were identified associated with energy metabolism [2-643 
oxoglutarate dehydrogenase (OGDH), and Lactate dehydrogenase (LDH)]; cytoskeleton-644 
based processes [Gamma-actin (ACTG1), Coronin 1B (CORO1B), and Pleckstrin (PLEK)]; or 645 
involved in protein degradation [Proteasome subunit type 8 (PSMB8)] [130]. Comparing the 646 
platelet proteome from patients with ACS to that of patients with stable CAD with 2DE-MS, 647 
the levels of proteins involved in cellular cytoskeleton [F-actin capping (CAPZA2), β-tubulin 648 
(TUBB), α-tubulin isotypes 1 and 2, Vinculin (VCL), Vimentin (VIM) and two Ras-related 649 
protein Rab-7b isotypes (RAB7B)], glycolysis [Glyceraldehyde-3-phosphate dehydrogenase 650 
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(GAPDH), Lactate dehydrogenase and two pPruvate kinase isotypes]; cellular-related 651 
antioxidant system (Manganese superoxide dismutase), cell survival [Proteasome subunit β 652 
type 1 (PSMB1)] and the expression and activity of Glutathione-S-transferase were 653 
significantly reduced in platelets from ACS patients compared to CAD patients [131]. 654 
Platelets from patients with non-ST segment elevation ACS versus stable CAD controls were 655 
analyzed by 2DE-MS. The identified differentially expressed proteins were involved in 656 
cellular cytoskeleton [Actin Cytoplasmatic-1 (ACTB), Alpha-actinin-1 (ACTN1), Caldesmon 657 
(CALD1), F-actin-capping protein subunit beta (CAPZB), Filamin-A (FLNA), Myosin-9 (MYH9), 658 
Talin-1 (TLN1), Tropomyosin alpha chain 3 (TPM3), Zyxin (ZYX)], signaling [Adenylyl cyclase-659 
associated protein 1 (CAP1), FYN-binding protein (FYB), Integrin-linked protein kinase (ILK), 660 
Proto-oncogene tyrosine-protein kinase Src (SRC), Rho GDP-dissociation inhibitor 2 661 
(ARHGDIB)] and ECM [Serum Albumin, Secreted protein acidic and rich in cysteine (SPARC)], 662 
vesicles/secretory trafficking pathway [Dynamin-1-like protein (DNM1L), Ras-related protein 663 
Rab-27B (RAB27B), -6B (RAB6B), -11A (RAB11A)] [132]. 664 
Alterations in the platelet proteome have also been associated with HFpEF. Raphael et al. 665 
analyzed the proteome of platelets from three groups: 1) patients hospitalized with 666 
symptoms of HFpEF, 2) the same subjects several weeks later without symptoms and 3) 667 
control subjects. Among the 6102 proteins identified by mass spectrometry, S100A8 was 668 
found to be consistently expressed in HFpEF patients compared to controls. The levels of this 669 
protein were also found increased in the plasma of subjects with HFpEF in an external 670 
cohort. To investigate whether S100A8 is causal or only associated with the disease, its 671 
effects were further assessed in human induced pluripotent stem cell-derived 672 
cardiomyocytes. The results indicated direct effects of S100A8 on the electrophysiological 673 
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and calcium handling profile and suggest that this protein may be causally contributing to 674 
HFpEF [133]. 675 
 676 
7. Factors with an impact on cardiovascular biomarkers 677 
7.1 Sex and ethnicity 678 
Alterations in the plasma levels of CVD biomarkers are also associated with sex and ethnic 679 
differences and may have value in individualized CVD risk assessment. In a Mayo Clinic study, 680 
uniplex and multiplex assays were used to measure the circulating levels of 47 candidate 681 
CVD markers in men and women of African-American (AA) and non-Hispanic White (NHW) 682 
ethnicity. Female gender was associated with higher levels of inflammatory markers, 683 
adipokines, lipoproteins, natriuretic peptides, vasoconstrictor peptides and markers of 684 
calcification and thrombosis. AA ethnicity was associated with higher levels of inflammatory 685 
markers, leptin, vasoconstrictor-antidiuretic peptides and markers of calcification and 686 
thrombosis and with lower levels of adiponectin and vasodilator-natriuretic peptides [134].  687 
7.2 Diet 688 
Polyphenol rich diets are associated with reduced risk of CVD, hence their potential effects 689 
on CVD biomarkers may be relevant. A pilot study was conducted to detect quantitative 690 
differences in the urinary CAD biomarkers (CAD238 [13]) caused by short-term consumption 691 
of a polyphenol rich (P-R) drink. A group of overweight healthy subjects were randomized to 692 
P-R drink or placebo for two weeks. Following urinary analysis by CE-MS, 27 polypeptides 693 
that displayed more than 4-fold difference between the two groups were detected. Among 694 
these, seven were included in CAD238, five of which [Fibrinogen alpha chain (FGA) [607-695 
622], Collagen alpha-1(I) chain (COL1A1) [543-588], Collagen alpha-2(V) chain (COL1A2) 696 
[1209-1225], Xylosyltransferase 1 (XYLT1) [51-66], Ig kappa chain C region (IGKC) [9-23]] 697 
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changing towards the healthy profile while two of them [Alpha-1-antitrypsin (SERPINA1) 698 
[276-295] and Collagen alpha-1(I) chain (COL1A1)[1095-1106]] changing towards CAD. Based 699 
on these results the authors suggested that P-R drink may have beneficial effects in CAD 700 
prevention [135]. More recently, the same group, in an effort to evaluate the impact of olive 701 
oil (OO) consumption in CVD prevention, investigated the impact of diet supplementation 702 
with OO, either low or high in phenolics, on urinary proteomic biomarkers (CAD238 panel). A 703 
significant improvement in the scoring of the CAD238 panel after supplementation with OO 704 
for 6 weeks was demonstrated, indicating a benefit of OO in preventing CVD [136].  705 
7.3 CKD 706 
CVD could also be a secondary endpoint in patients with CKD disease. To address this issue, 707 
Schiffer et al., performed a diagnostic phase I/II study in which CE-MS was applied to analyze 708 
plasma specimens from CKD stage 5D patients suffering from vascular disease. Comparative 709 
analysis identified 13 novel biomarkers for CVD of which four were identified by tandem MS 710 
as fragments of Collagen alpha-1 type I and III and one as fragment of Apolipoprotein C3 711 
(APOC3). The markers were validated in an independent blinded cohort and enabled 712 
distinguishing mild and severe CVD with good sensitivity and specificity, suggesting that this 713 
specific polypeptide pattern in the plasma of CKD patients reflects CVD [137]. 714 
 715 
7.4 Ageing 716 
Urinary proteomics was also employed to investigate the proteomic transition from normal 717 
ageing to age-related pathological complications including CVD. Using CE-MS in a study 718 
including over 10000 subjects, 112 age-correlated peptides (mainly originated from collagen, 719 
uromodulin and fibrinogen) were identified. Pathway analysis revealed perturbations in 720 
collagen homeostasis, trafficking of toll-like receptors and endosomal pathways being 721 
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associated with ageing in general, whereas increased degradation of insulin-like growth 722 
factor-binding proteins (IGFBPs) was observed in pathological ageing only [138]. 723 
 724 
7.5 Hemodialysis 725 
Plasma proteomic analysis of the HDL fraction may enable identification of candidate 726 
biomarkers associated with cardiovascular risk in end-stage renal disease (ESRD) patients 727 
undergoing hemodialysis. To this end, Mange et al. investigated the proteome of HDL 728 
isolated from plasma of hemodialysis patients at high risk for CVDs and healthy volunteers. 729 
Using iTRAQ labeling and nano-LC/MS/MS analysis, forty proteins differentially expressed in 730 
the two groups were identified. These proteins were primarily involved in lipid metabolism, 731 
inflammation, complement activation and metal cation homeostasis. Among them, 732 
Apolipoprotein C2 (APOC2) and Apolipoprotein C3 (APOC3) were found elevated in 733 
hemodialysis patients whereas Serotransferrin was reduced after validation in an 734 
independent population set. The authors conclude that the identified proteins are linked to 735 
HDL dysfunction in chronic hemodialysis patients [139]. 736 
 737 
8. Data integration in CVD 738 
The advantage of integrating different omics approaches has previously been shown in the 739 
management of chronic kidney disease [140]. Not only is the identification of a broader 740 
range of biomarkers possible, but also the systemic understanding of related molecular 741 
mechanisms is achievable, both contributing to improving disease management [3,4]. 742 
Towards this end, we performed gene ontology analysis of all the biomarkers summarized in 743 
the tables of this review through Cytoscape. Inflammation (acute, humoral, complement 744 
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activation etc.), wound healing and coagulation (platelet activation, degranulation, fibrin clot 745 
formation), proteolysis and extracellular matrix organization, and handling of cholesterol 746 
and LDL were among the most significantly pathways and biological functions reflected by 747 
the proteomic changes observed in CVD (data provided in supplementary table 2).  748 
First reports on combining different omics traits were published recently. The integration of 749 
genomics and metobolomics has been explored in CVD and findings have shown an added 750 
value in the approach [141]. An integrated metabolomics and genome-wide association 751 
study (GWAS) has revealed that single nucleotide polymorphisms can explain variances 752 
observed with some metabolite levels [142]. Through the integration of the transcriptomic 753 
with proteomic findings from myocardial tissues global changes in dilated cardiomyopathy 754 
(DCM) in genes, proteins and pathways involved in cardiac function were unraveled [143]. A 755 
network biology approach that combined genomic and proteomic data was developed and 756 
distinguished pathological from physiological left ventricular hypertrophy (LVH) [144]. In 757 
another study, genetic, transcriptome and protein analyses of titin truncations provided 758 
evidence into the mechanisms of end-stage DCM [145]. A strategy combining proteomics 759 
with metabolomics was applied in human cardiac tissues from individuals with normal heart 760 
or patients with ischaemic (ISCM) and idiopathic dilated cardiomyopathies (IDCM). This 761 
study enabled the characterization of the differential regulation of molecular pathways and 762 
metabolism in ISCM and IDCM for the first time [146]. Apart from the potential to elucidate 763 
mechanisms of disease pathogenesis, the integrative omics approaches also hold promise 764 
for personalised medicine [147]. Combined, the published reports suggest that systems 765 
biology approaches underpinned by omics strategies in animal models and patients have the 766 
potential to aid in the dissection of the complicated networks interfering in cardiovascular 767 
pathophyshiology and lead to the development of novel diagnostic and therapeutic 768 
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modalities [119,148-150]. However, although the benefits of omics integration are quite 769 
obvious, it is very challenging to achieve a successful integration. A major challenge 770 
associated with data integration is the heterogeneity of data generated by omics 771 
technologies. There is clearly an urgent need to develop robust algorithms that will facilitate 772 
this process. 773 
9. Expert commentary 774 
Significant progress towards the development of state of the art proteomic technologies 775 
applicable in the context of CVD has been made. These advancements include improvement 776 
of sample preparation methods for detection even of the low-abundance proteins as well as 777 
the development of high-throughput proteomic profiling techniques that enable the 778 
detection of multiple candidate biomarkers rapidly and with high accuracy. Although early 779 
studies focused mainly on tissue and plasma proteomics, recent studies also targeted other 780 
biological sources such as urine, extracellular vesicles and sub-cellular proteomes for 781 
biomarker discovery. The number of potential biomarkers that have arisen through the 782 
application of proteomic technologies has substantially increased in the past few years. In a 783 
considerable number of studies, efforts have been put on unraveling panels of proteomic 784 
biomarkers. These appear to be of higher stability and accuracy than single biomarkers, since 785 
panels are better suited to display the complex disease pathophysiology [151]. 786 
However, we also see substantial shortcomings in unfortunately many studies. As outlined 787 
by us and others in detail (e.g. [152-154]), the mere detection of the association of a protein 788 
with disease is insufficient to support claims for biomarkers. As a minimum a potential 789 
biomarker must have a defined context-of-use and demonstrate a significant improvement 790 
of the current state-of-the-art, in the population it is intended to be used. Unfortunately, 791 
many studies fall short of this minimal requirement, and consequently the biomarker value 792 
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and reliability of findings cannot be readily attributed. In addition, although other factors 793 
and diseases, like diabetes type 2 and CKD, have significant impact on cardiovascular 794 
biomarkers and should be taken into consideration when performing such studies, this is 795 
frequently not attempted. Progress has been made in recent years in the development of 796 
proteomics technologies. Application of these novel approaches in the discovery process 797 
may result in additional, novel findings. In addition, major efforts should be directed towards 798 
actual assessment of the value of existing biomarkers for a specific context of use, in the 799 
relevant population, and in the light of the current state-of-the-art (currently routinely used 800 
biomarkers and pertinent demographic information). This has been outlined several years 801 
ago for bladder cancer [155], but the exact same considerations hold true for cardiovascular 802 
disease.  803 
 804 
10. Five-year view 805 
Summarizing the recent progress in the discovery of proteomic biomarkers for CVD, it is 806 
obvious that despite the plethora of studies performed in this field, only few of them appear 807 
close to clinical implementation. A significant number of studies stops at the discovery phase 808 
without subsequent validation of the findings. Since many of the studies cited in this review 809 
are very recent, we hope for a rapid progress in biomarker validation the next years.  810 
Nevertheless, some biomarker panels have arisen the recent years holding promise for 811 
better management of CVD based on reported validation studies. It appears that the most 812 
relevant context of use for proteomics biomarkers in CVD is enabling early detection and 813 
prognosis.  814 
The next step for these panels is to be validated in blinded studies and subsequently 815 
approved by the regulatory authorities for clinical application. An example is the application 816 
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of a proteomic biomarker panel for CKD detection: the panel, CKD273, was developed based 817 
on over 600 samples [156], and subsequently evaluated and validated in multiple studies 818 
[157-159]. As a result, this urinary proteome-based panel is now being used in patient 819 
stratification in PRIORITY, a large multicentric randomized controlled trial [160,161] and has 820 
also received a letter-of-support from the US-FDA 821 
(http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/UCM518268.pdf). 822 
As depicted in Figure 4, the current state-of-the-art allows assessment of CVD with high 823 
confidence at late stage, when significant and frequently irreversible organ damage has 824 
occurred. Hence it seems biomarkers enabling detecting established disease are of very 825 
little, if any value. The potential of proteomic biomarkers appears in the early detection of 826 
disease, when disease-initiating molecular processes are already ongoing, but clinical 827 
symptoms are not detectable. This is also supported by the thoughts outlined in Figure 1: 828 
the hypothesis that proteins are the cause of CVD onset and progression. At an early stage 829 
also intervention will be most effective, ideally even preventing onset of disease.  830 
Such approaches also depend on a holistic understanding of CVD processes, which will be 831 
one of the biggest challenges in forthcoming studies. In the near future, the development of 832 
systems biology approaches through the integration of omics technologies will provide a 833 
more systematic insight into CVD [3,4]. Integration of the proteomics data with findings from 834 
other omics approaches and bioinformatics analysis will pave the way for the development 835 
of novel biomarker panels detecting early stages of the disease leading to CVD prevention. A 836 
new era of proteomics towards personalized cardiovascular medicine will hopefully begin 837 
soon. 838 
 839 
11. Key issues 840 
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 CVD remains the major cause of morbidity and mortality worldwide, knowledge on 841 
molecular mechanisms and potential drug targets as well as validated biomarkers 842 
guiding intervention are urgently required. 843 
 Proteomics has the ability to allow insights into the mechanisms underlying 844 
cardiovascular disease, should enable defining disease on a molecular level. 845 
 Advancements and development of state of the art proteomics technologies have 846 
facilitated the high-throughput analysis of many and different samples.  847 
 Progress has been also made the recent years towards the development of 848 
biomarker panels, demonstrating superiority over single biomarkers.  849 
 A list of promising results and multiple potential biomarkers exists, but has to be 850 
investigated and validated in detail to have an actual impact, improve patient care in 851 
the near future. 852 
 Other factors and systemic disorders have an impact on cardiovascular biomarkers 853 
and therefore should be considered when analyzing data from discovery and 854 
validation phases. 855 
 Verification of the proteomic findings in appropriately powered studies appears 856 
imperative now, to receive approval from the regulatory authorities and enable 857 
implementation. 858 
859 
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Figure 1: Graphic depiction of the information obtained from the different approaches. 860 
Histology can give information on microscopic structural changes. Subcellular structures, and 861 
even more the molecules involved in the molecular pathology can generally not be assessed. 862 
In contrast, proteome analysis does not give information on morphological changes, but 863 
gives information on global protein changes, which can be associated with the molecular 864 
changes in disease. Proteins represent the most appropriate targets of therapeutic drugs, 865 
hence, proteome analysis can give guidance on the molecular structures to be targeted in 866 
therapy, an information that can generally not be obtained from histology. Adapted with 867 
permission from [162]. 868 
 869 
Figure 2: Graphical depiction of the main two different routes clinical proteomics 870 
approaches can take: towards biomarker discovery, or a Systems Medicine approach 871 
towards "modelling disease": The biomarker approach (left) requires identification of 872 
distinct potential biomarkers that are subsequently verified, and then applied in the 873 
appropriate clinical setting. If benefit can be demonstrated, they should be 874 
implemented/routinely applied. The Systems medicine approach takes advantage of the 875 
breadth of data, including literature sources, aims at molecular modelling of disease and 876 
predicting key structures. These are then verified (first valid result), and subsequently their 877 
value as potential targets is investigated in appropriate interference studies. If positive, 878 
drugs can be developed, tested, and, if beneficial, should be applied. Starting with the same 879 
or similar data, the downstream utilization (and the associated issues) is quite different, but 880 
ultimately in both cases we aim at investigating proteomics to improve patient care. 881 
 882 
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Figure 3. Schematic representation of the workflow followed in cardiovascular proteomic 883 
studies. A plethora of biological sources including arterial tissue, cardiac tissue, tissue 884 
secretome, blood, urine, thrombus, circulating cells and platelets have already been used to 885 
investigate the proteome alterations in cardiovascular disease (CVD). Analysis of these 886 
proteomes through global proteomics (discovery phase) and targeted proteomics (validation 887 
phase) approaches will make possible the identification of novel candidate biomarkers for 888 
better management of CVD. Of note, there are four biomarkers recommended for clinical 889 
use: 1) Cardiac Troponin T and Troponin I, 2) B-type natriuretic peptide (BNP), 3) C-reactive 890 
protein (CRP) and D-dimer, 4) Apolipoprotein A-I.     891 
 892 
Figure 4. Early diagnosis and/or prognosis of diseases improves chances for a better 893 
outcome for the patients. The initiation of molecular processes that result in (chronic) 894 
diseases can be detected based on the decisive molecular changes, using proteomic 895 
technologies, substantially prior to advanced organ damage. In this early stage, molecular 896 
changes could be reverted, and onset of clinically relevant disease could be prevented. As a 897 
minimum, further progression can be slowed down by applying of appropriate therapeutic 898 
interventions and/or changes to the lifestyle. At a later stage, the disease becomes clinically 899 
evident, as a result of the organ damage. However, at this point in time curative treatment is 900 
not possible anymore, only disease progression can possibly be delayed to some extend 901 
(although with moderate success, as also evident by the multiple trials that failed). Reprinted 902 
with permission from [163]. 903 
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